-M J Ratain Researcher Activity Profile

Research Author Detailed Information 

M J Ratain Publication Rate By Year

M J Ratain has published 2 paper(s) in 2006, 25 paper(s) in 2007, for a total of 27 research publications in total.

M J Mj Ratain Author Information

LAST NAME: ratain

FIRST NAME: M J

INITIALS: mj

AFFILIATION:

Papers

M J Ratain's Publication Record

1. The pharmacogenetics research network: from SNP discovery to clinical drug response. Year Published: 2007
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA. kathy.giacomini@ucsf.edu
2. Rapamycin: something old, something new, sometimes borrowed and now renewed. Year Published: 2007
Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA.
3. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Year Published: 2006
Section of Hematology/Oncology, Department of Medicine, Committees on Clinical Pharmacology and Pharmacogenomics and Molecular Medicine, and Cancer Research Center, The University of Chicago, Chicago, Illinois 60637, USA. mratain@medicine.bsd.uchicago.edu
4. Pharmacogenomics: challenges and opportunities. Year Published: 2006
Vanderbilt University, Nashville, Tennessee, USA. dan.roden@vanderbilt.edu
5. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Year Published: 2007
Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
6. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Year Published: 2007
Wake Forest University School of Medicine, Winston-Salem, NC 27157-1082, USA. aamiller@wfubmc.edu
7. Clarification Regarding "Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties" and the Accompanying Commentary, "Phase II Cancer Trials: Out of Control?". Year Published: 2007
Massachusetts General Hospital, Boston, Massachusetts.
8. The investigational drug steering committee. Year Published: 2007
Cancer Research Center, Division of Biological Sciences, The University of Chicago, Chicago, IL, USA.
9. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Year Published: 2007
Authors' Affiliations: Section of Hematology/Oncology, Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, University of Chicago, Chicago, Illinois.
10. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines. Year Published: 2007
Authors' Affiliations: Departments of Medicine and Human Genetics, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, The University of Chicago.
11. Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity. Year Published: 2007
University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637. mratain@medicine.bsd.uchicago.edu.
12. The value meal: how to save $1,700 per month or more on lapatinib. Year Published: 2007
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
13. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. Year Published: 2007
Department of Health Studies, University of Chicago, Chicago, IL 60637, USA.
14. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?". Year Published: 2007
15. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Year Published: 2007
Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
16. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. Year Published: 2007
Section of Hematology, Cancer Research Center, Committee on Clinical Pharmacology and Pharmacogenomics, MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL 60637, USA. cdaugher@medicine.bsd.uchicago.edu
17. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Year Published: 2007
18. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Year Published: 2007
Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
19. Recommended changes to oncology clinical trial design: Revolution or evolution? Year Published: 2007
University of Chicago, Chicago, IL, USA.
20. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Year Published: 2007
Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
21. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Year Published: 2007
University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois, USA.
22. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?". Year Published: 2007
23. The investigational drug steering committee. Year Published: 2007
Cancer Research Center, Division of Biological Sciences, The University of Chicago, Chicago, IL, USA.
24. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Year Published: 2007
25. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Year Published: 2007
Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
26. Recommended changes to oncology clinical trial design: revolution or evolution? Year Published: 2007
University of Chicago, Chicago, IL, USA. mratain@medicine.bsd.uchicago.edu
27. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. Year Published: 2007
Department of Health Studies, University of Chicago, Chicago, IL 60637, USA.